Form 4: ImmunityBio's Chief Accounting Officer Receives Stock Options and Restricted Stock Units

Regan J Lauer, Chief Accounting Officer of ImmunityBio, Inc., reports the acquisition of stock options and restricted stock units.

Summary

• Regan J Lauer, the Chief Accounting Officer of ImmunityBio, Inc. (IBRX), filed a Form 4 on February 12, 2025, reporting transactions related to the company's equity securities.
• On February 10, 2025, Lauer acquired 16,447 restricted stock units (RSUs) and 56,250 stock options.
• The RSUs vest in three annual installments starting on February 10, 2026, and represent a contingent right to receive one share of ImmunityBio common stock per unit.
• The stock options, with an exercise price of $3.39, also vest in three annual installments starting on February 10, 2026, and expire on February 10, 2035.
• Both the RSUs and stock options are subject to Lauer's continued service with ImmunityBio.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholder value.

Positives

• The granting of RSUs and stock options aligns the interests of the Chief Accounting Officer with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs and stock options.

Industry Context

Granting stock options and RSUs to key executives is a common practice in the biotechnology industry to incentivize performance and retain talent. This aligns with standard compensation practices in similar companies.

Comparison to Industry Standards

• Companies like Amgen (AMGN) and Gilead Sciences (GILD) also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally in line with industry norms for companies of ImmunityBio's size and stage of development.
• Comparing the total equity compensation value to similar roles at comparable companies would provide a more comprehensive assessment.

Stakeholder Impact

• Shareholders: The grant of equity may be viewed positively as it incentivizes management to improve company performance.
• Employees: The grant of equity to a key executive may boost morale and reinforce the company's commitment to its employees.

Key Dates

Keywords

Form 4, ImmunityBio, IBRX, Regan J Lauer, Chief Accounting Officer, Restricted Stock Units, Stock Options, Beneficial Ownership, Equity Securities